Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Sunitinib and Atrial Trabeculae Contractility (SCAR)

This study has been completed.
Information provided by (Responsible Party):
G. Rongen, Radboud University Identifier:
First received: November 22, 2010
Last updated: April 30, 2014
Last verified: April 2014


Recently, sunitinib (a tyrosine kinase inhibitor that is used for treatment of metastatic renal carcinoma and gastrointestinal stroma tumors) has been associated with development of heart failure, possibly by off-target inhibition of AMP-protein kinase. The investigators hypothesize that sunitinib reduces the contractile ability of myocardium and the tolerance against ischemia-reperfusion and that activators of AMP-protein kinase such as atorvastatin and AICAR reverse this unwanted effect of sunitinib.


The primary objective of the study is to investigate the effect of sunitinib on ex-vivo atrial contractile force in absence and presence of ischemia-reperfusion.

A secondary objective is to explore if atorvastatin or AICAR prevent sunitinib-induced deterioration of contractile function of human atrial trabeculas. Study design: Lab

Heart Failure

Study Type: Observational
Study Design: Observational Model: Case-Only
Official Title: The Influence of Sunitinib on Contractility of Human Atrial Trabeculae

Resource links provided by NLM:

Further study details as provided by Radboud University:

Primary Outcome Measures:
  • Force [ Time Frame: 200 minutes ] [ Designated as safety issue: No ]
    The developed force in ex vivo atrial trabeculae during standardized stimulation.

Secondary Outcome Measures:
  • Speed [ Time Frame: 200 minutes ] [ Designated as safety issue: No ]
    The difference in averaged maximal speed of tension reduction during relaxation between two trabeculae

  • Maximal Speed [ Time Frame: 210 minutes ] [ Designated as safety issue: No ]
    The difference in averaged maximal speed of tension development during contraction between two trabeculae.

Biospecimen Retention:   None Retained

Atrial tissue

Enrollment: 20
Study Start Date: November 2010
Study Completion Date: April 2014
Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)
With/without sunitinib
Two trabeculas will be isolated and one will be exposed to sunitinib and the other to normal buffer solution. Both will be stimulated to contraction during 200 minutes.
With/without sunitinib IP
Two trabeculas will be isolated and one will be exposed to sunitinib and the other to normal buffer solution. Both will be stimulated to contraction and ischemia/reperfusion

Detailed Description:

Study population: 44 (+22) patients undergoing CABG cardiac surgery with extracorporal circulation Intervention (if applicable): none (pharmacological interventions will only be performed ex-vivo in isolated atrial tissue) Main study parameters/endpoints The developed force in ex vivo atrial trabeculas during standardized stimulation.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

44 patients undergoing cardiac surgery with extracorporal circulation


Inclusion Criteria:

  • Cardiac surgery with extracorporal circulation

Exclusion Criteria:

  • Use of oral antiarrhythmics
  • theophylline use
  • Use of sulfonylureas
  • Atrial arrythmias
  • Right ventricular failure
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01246778

Radboud University Nijmegen Medical Centre
Nijmegen, Netherlands, 6500HB
Sponsors and Collaborators
Radboud University
Principal Investigator: G. A. Rongen Radboud University
  More Information

No publications provided

Responsible Party: G. Rongen, Prof. dr. Rongen, Radboud University Identifier: NCT01246778     History of Changes
Other Study ID Numbers: SCAR
Study First Received: November 22, 2010
Last Updated: April 30, 2014
Health Authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Additional relevant MeSH terms:
Heart Failure
Cardiovascular Diseases
Heart Diseases
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Antineoplastic Agents
Growth Inhibitors
Growth Substances
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses processed this record on November 25, 2014